哮喘患者慢性鼻窦炎的管理模式:基于证据的综述与推荐
本综述系统检索了PubMed、Embase和Cochrane数据库,共筛选5903篇文章,最终53篇纳入定性合成,评估哮喘合并慢性鼻窦炎(CRSwA)的管理策略。强证据支持口服和局部药物改善鼻窦结局,中至强证据支持内镜鼻窦手术(ESS)改善鼻窦和哮喘生活质量,生物制剂强效改善主客观结局。结论支持阶梯式管理,从传统非生物制剂口服和局部药物开始,升级至ESS和生物制剂等二线治疗。
要点
- 强证据支持口服和局部药物改善CRSwA患者的鼻窦特异性结局,低级别证据显示可改善肺功能和/或哮喘控制。
- 中至强证据表明ESS改善鼻窦和哮喘特异性生活质量,数据提示对哮喘控制有积极影响,但肺功能改善证据不足至低。
- 生物制剂强效改善主客观鼻窦和哮喘特异性结局;证据支持阶梯式管理,从传统药物开始升级至ESS和生物制剂。
核心结论
- 证据支持对哮喘合并慢性鼻窦炎个体采用阶梯式管理,从传统非生物制剂口服和局部药物开始,升级至ESS和生物制剂等二线治疗。
- CRSwA患者的最佳治疗常需同时进行针对哮喘的定向管理,因为并非所有CRS干预措施都影响哮喘状态。
研究设计与样本
- 使用PubMed、Embase和Cochrane Review Databases进行系统综述,覆盖CRSwA的管理策略。
- 共筛选5903篇文章,70篇纳入全文分析,应用排除标准后53篇构成定性合成。
- 对证据水平进行分级,并提供获益-危害评估、价值判断和推荐。
主要发现
- 强证据确认口服和局部药物对CRSwA个体鼻窦特异性结局的益处;低级别证据显示这些药物改善肺功能和/或哮喘控制。
- 中至强证据提示ESS改善鼻窦和哮喘特异性生活质量;证据不足至低表明ESS改善肺功能,但数据提示对哮喘控制有积极影响。
- 生物制剂强效改善主客观鼻窦和哮喘特异性结局。
关键数值与推荐
- 强证据:口服和局部药物改善鼻窦特异性结局。
- 低级别证据:口服和局部药物改善肺功能和/或哮喘控制。
- 中至强证据:ESS改善鼻窦和哮喘特异性生活质量。
- 证据不足至低:ESS改善肺功能;数据提示对哮喘控制有积极影响。
- 强证据:生物制剂改善主客观鼻窦和哮喘特异性结局。
临床怎么用
- 证据支持对CRSwA患者采用阶梯式管理,从传统非生物制剂口服和局部药物开始,升级至ESS和生物制剂等二线治疗。
- CRSwA患者的最佳治疗常需同时进行针对哮喘的定向管理,因为并非所有CRS干预措施都影响哮喘状态。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the significant morbidity associated with chronic rhinosinusitis (CRS) in individuals with asthma (CRSwA), there is a paucity of codified, evidence-based management strategies for CRS in this population. METHODS: Using PubMed, Embase, and Cochrane Review Databases, a systematic review was performed covering management strategies for CRSwA. A total of 5903 articles were screened, and 70 were included for full-text analysis. After application of exclusion criteria, 53 articles comprised the qualitative synthesis. The level of evidence was graded and benefit-harm assessments, as well as value judgment and recommendations, were provided RESULTS: Strong evidence confirms the benefit of oral and topical medications on sinonasal-specific outcomes in individuals with CRSwA; there is low-grade evidence demonstrating that these agents improve lung function and/or asthma control. Moderate to strong evidence suggests that endoscopic sinus surgery (ESS) improves both sinonasal- and asthma-specific quality of life. Although there is insufficient to low evidence to indicate that ESS improves pulmonary function in this population, data indicate a positive impact of this intervention on asthma control. Biologic medications strongly improve both subjective and objective sinonasal- and asthma-specific outcomes. CONCLUSION: Evidence supports managing CRS in individuals with CRSwA in a stepwise fashion, starting with traditional nonbiologic oral and topical medication, and escalating to second-line treatments, such as ESS and biologics. Optimal treatment of individuals who have CRSwA often requires concurrent, directed management of asthma, as not all CRS interventions impact asthma status.
引用
- Gill AS, Alt JA, Detwiller KY, et al. Management paradigms for chronic rhinosinusitis in individuals with asthma: An evidence-based review with recommendations. Int Forum Allergy Rhinol. 2023. PMID: 36579899. doi:10.1002/alr.23130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。